Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Patients with variants outside these criteria had FAP-related extracolonic manifestations, colorectal cancer aged <40, somatic KRAS c.34G > T variant in the tumor or a first-degree relative with >10 adenomas. 31527860 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Twenty-five CRC biopsies and 15 adenoma were analyzed for KRAS mutations by DNA sequencing (Sanger sequencing), and all 50 patients (35 CRCs and 15 adenomas) were evaluated by immunohistochemistry for the CR-1 protein expression. 31692030 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE As a result, a classification model built with methylation of SDC2 and SFRP2, KRAS mutations and hemoglobin showed a sensitivity of 91.4% for colorectal cancer and 60% for adenoma with the specificity of 86.1%. 31456088 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 PosttranslationalModification group BEFREE Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas. 31179849 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker group BEFREE Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions. 30997628 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker group BEFREE Additionally, we performed multiregional, targeted next-generation sequencing (NGS) of adenomas and unmasked extensive heterogeneity, affecting known drivers such as APC, KRAS and mismatch repair (MMR) genes. 30166531 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker group BEFREE Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas. 29575536 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker group BEFREE A model of K-Ras-initiated lung cancer was used to follow the transition of precancerous adenoma to adenocarcinoma. 29930325 2018
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Hierarchical clustering isolated three relevant clusters: (i) cluster of microsatellite stable mucinous adenocarcinomas (54%) with KRAS mutation, and frequent MGMT changes, more frequently located in the left colon, often associated with contiguous precursor adenoma; (ii) cluster of BRAF-mutated mucinous adenocarcinomas (28%) with either microsatellite instability-high or microsatellite stable status, occurring in elderly female patients, nearly all located in the right colon, having the signature of serrated pathway of carcinomas; and (iii) a heterogeneous cluster of microsatellite instability-high mucinous carcinomas (18%), including inherited colorectal carcinomas, displaying a high-grade histological pattern. 28429715 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE In the univariate analysis, KRAS mutations were associated with the development of metachronous advanced polyps (OR: 2.36, 95% CI: 1.22-4.58; P = 0.011), and specifically, advanced adenomas (OR: 2.42, 95% CI: 1.13-5.21; P = 0.023). 28953955 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE In conclusion, our results indicate that MLH1-hypermethylated BRAF wild-type colorectal carcinomas can harbor KRAS mutations and arise from precursor polyps resembling conventional tubular/tubulovillous adenomas. 27438990 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE KRAS mutations may, in part, drive the histologic progression of adenomas toward a villous histology and higher grades of dysplasia. 26910894 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Based on the current knowledge, the sessile serrated adenoma/polyp may be the major precursor of MLH1-methylated CIMP-H CRCs, whereas MLH1-unmethylated CIMP-H CRCs may develop predominantly from KRAS-mutated traditional serrated adenomas and less commonly from BRAF-mutated traditional serrated adenomas and/or sessile serrated adenomas/polyps. 26883113 2016
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE BRAF mutation was more frequent, whereas KRAS mutation was less frequent in the SSA/P series as compared with the adenoma series. 24925057 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker group CTD_human The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling. 25851810 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE P16 staining was lost in the advanced areas of 55% of BRAF mutant traditional serrated adenomas compared with 10% of the advanced areas of KRAS mutant or BRAF/KRAS wild-type traditional serrated adenomas. 25216220 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 AlteredExpression group BEFREE Endoscopic papillectomy and KRAS expression in the treatment of adenoma in the major duodenal papilla. 25971870 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE In contrast, GCHPs have been associated with the KRAS mutation (KRAS-mut), which are infrequently seen in dysplastic serrated sessile adenomas. 25350766 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Together, this may suggest that two molecular pathways, intermediate methylation associated with KRAS mutations and LST-G morphology, and low methylation associated with CTNNB1 activation and LST-NG morphology, might be involved in LST development, and that involvement of TP53 mutations could be important in both subtypes in the development from adenoma to cancer. 24590867 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 AlteredExpression group BEFREE Mixed effects models revealed that mutations in APC, BRAF and KRAS occur at the transition from normal to adenoma stages whilst the hypermethylation of the Wnt antagonists continued to accumulate during the transitions from adenoma to carcinoma stages. 25432628 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Clinical findings, morphologic features, immunophenotypes and KRAS alterations were investigated in 7 patients with intraductal tubular adenomas, 16 patients with gastric-type intraductal papillary mucinous neoplasms and 6 patients with intraductal tubulopapillary neoplasms. 25245835 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 Biomarker group BEFREE M2PK showed a detection rate of 40.3% for adenomas but the combination of M2PK and KRAS abnormalities was found in only 5.7% of adenomas (P <0.01). iFOBT was false positive in 31.8% of cases in which colonoscopy excluded neoplastic lesions, while the coexistence of molecular and enzymatic abnormalities was more specific with false positive rates between 8.3% and 9.0% (P <0.05). 24852854 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE In summary, we identified significant KRAS mutation discordance between the adenoma and carcinoma component of the lesion. 24998492 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE KRAS mutations were detected in 13.6% of the precursor lesions, namely in adenomas and in HPs, but in no serrated adenoma. 25050586 2014
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.400 GeneticVariation group BEFREE Within the high-frequency methylation adenoma class a subset of adenomas had mutant KRAS. 24793120 2014